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Severe hemoglobinopathies, namely thalassemia major 
and sickle cell disease, are the most frequent life-
threatening non-communicable disease of children 
globally: A minimum estimate of 300.000 newborns yearly 
have some symptomatic globin disorder, these births 
occur largely in low- and middle-income countries (LMICs) 
where prevention and management programs are often 
lacking or insufficient1,2. 
Hematopoietic stem cell transplantation, also known as 
blood or marrow transplantation (BMT), is the only 
established curative modality with success rates over 
85% in low risk children with a compatible sibling3–5, 
moreover, BMT can normalize long-term health-related 
quality of life (HRQoL)6,7 and be highly cost effective8,9. 
However, there is a dire shortage of BMT centers in 
hemoglobinopathy-prone regions10 which often fall in the 
low- and middle-income country (LMIC) strata, so that 
many families have to migrate to affluent countries 
seeking cure for their beloved ones; this not only 
aggravates misery, psychological and economical burden 
but perpetuates the hemorrhage of professional and 
financial resources to high-income countries (HIC). 
Within structured collaboration programs low-risk 
matched-related BMT can be associated with very good 
results even in startup centers directly in LMICs11,12 and 
thus may provide a unique opportunity for saving lives, 
improve HRQoL, decrease financial burden of disease 
and promote capacity-building, research & development, 
and health care strengthening13. 
BMT indications and outcomes: HICs vs. LMICs: The 
spectrum of BMT indications and procedures differ 
between West and East10: in North America and Europe 
hematological malignancies are the most frequent 
indication and unrelated donors are often employed 
because of small average family size. In the Middle East 
and Asia non-malignant disorders, e.g. 
hemoglobinopathies and aplastic anemia, tend to be most 
common indications and matched related donors more 
frequently available14–16. Moreover, in addition to financial 
and logistic issues, the very limited use of unrelated 
volunteer donors in the East is also due to the fact that 
non-malignant disorders require stringent HLA matching 
and non-Caucasian ethnicities are generally 
underrepresented in donor registries17. Lastly, results 
using partially matched family doors for so called 
haploidentical transplantation, typically the mother or 
father, are increasingly encouraging18. 
There is no evidence that, at least for low-risk matched 
related BMTs, outcomes are substantially different in 
HICs compared to LMICs. Gliebel et al. assessed the 
impact of Human Development Index (HDI) on BMT 
results in adults with acute leukemia and found that 
transplantations performed in countries with an upper HDI 
were associated with improved leukemia-free survival, 
this however was not due to higher transplant-related 
mortality (TRM) but rather to higher relapse rates in 
LMICs, suggesting that the survival differences were 
probably related to patient selection and residual disease 
assessment rather than the BMT procedure itself19, and 
thus may not apply to non-malignant disorders. 
In the experience of the Cure2Children Foundation (C2C) 
in supporting the startup of centers in Pakistan and India 
performing primarily low-risk matched-related BMTs for 
severe thalassemia aided by a structured peer to peer 
collaborative platform20, outcomes where comparable to 
those obtained in Western centers21. There is also no 
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evidence that in LMICs the spectrum of transplant-related 
infections is substantially different compared to the 
West22,23. 
Cost issues  
BMT is one of the most expensive tertiary care 
procedures with costs generally above 150.000 USD in 
HICs24. Figure 1 compares the relative cost breakdown of 
BMT for adult leukemia in HICs to the one for childhood 
thalassemia in LMICs underlining several interesting 
points: a) the major difference is related to follow up 
costs, probably because chronic GVHD is far more 
common, and to some extend therapeutically desirable, in 
adult leukemia; b) the second major difference is in 
hospitalization charges, which are related mostly to 
differences in salaries but also to BMT units construction 
and maintenance, in fact, complex infection control 
environments may not be needed for low-risk matched-
related BMT in children with non-malignant diseases who 
arrive to transplant with no prior exposure to 
chemotherapy, no previous prolonged neutropenia 
episodes, no infections and in good general conditions12; 
c) diagnostics are also much less expensive in BMT for 
thalassemia since, for example, residual leukemia 
quantification or frequent chimerism analysis post BMT 
are not an absolute requirement as long as transfusion-
independency is achieved; d) drugs and transfusion 
support is also different because of patient size and 
complication frequency, particularly fungal infections, the 
treatment of which may substantially impact on final costs. 
In fact, in the C2C experience in Pakistan and India the 
incidence of possible, probable or proven fungal 
infections25 in young thalassemic children undergoing 
matched-related BMT is less than 2%23. Within an existing 
hospital facility, less than 100,000 USD where sufficient to 
renovate and fully equip a 4-bed start up BMT unit26. 
Increasing evidence suggest that complex and costly 
infection control environments may not be required27–29 
and established international guidelines do not call for 
stringent air control systems, at least for low-risk BMTs30.  
The cure of severe hemoglobinopathies as a 
capacity-building opportunity  
Optimal supportive care if often not available or not 
accessible in LMICs so that most children with severe 
hemoglobinopathies do not survive beyond 20 years of 
age and the risk of blood-borne infections, primarily 
hepatitis C, is still substantial32. 
 
Figure 1. Cost breakdown comparison of matched-
related BMT in HIC (adult leukemia24) and LMIC 
(children with thalassemia31); total cost $116,000* and 
$11,200 respectively (family support program not 
included) 
 As paradoxical as it may seem, BMT may actually be the 
best option for many patients with thalassemia in 
developing countries: It is a one-time procedure not 
depending on long-term access to appropriate medical 
care and at the same time greatly improves the quality of 
life for both patients and families by decreasing medical, 
psychological and financial burdens6,7. 
Buccal swab-based HLA-typing technology has greatly 
facilitated centralized compatibility testing so that there is 
no need to set up HLA laboratories locally, and patients 
can be easily typed worldwide and referred to BMT 
centers within South-South cooperation programs offering 
effective and cost-conscious BMT33. 
In the C2C-supported BMT network in Pakistan and India 
hinging on focused training and intensive online 
cooperation, low-risk matched-related BMT in children 
younger than 15 years is currently delivered with more 
than 95% thalassemia-free survival, a result at least as 
good as that obtained in HIC3, for an average cost of 
12.000 USD per BMT4,31. The realistic prospect of a 
definitive cure also improved compliance with supportive 
care and engaged families in cascade screening and 
prevention programs, e.g. most mothers of thalassemic 
children accepted the offer of free prenatal diagnosis for 
subsequent pregnancies. 
Because of large patient loads, there is great potential for 
expertise on specific disease curable by BMT, for 
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 example, Pakistan has at least 100 times the incidence of 
thalassemia compared to the West, and many cases have 
a compatible sibling donor due to large family size. As a 
result, many more transplants for young thalassemic 
children with a compatible donor are currently carried out 
in LMICs compared to Europe or North America34. 
However, to take advantage of this opportunity, 
Increasing efforts will have to focus on quality assurance 
platforms20 and outcome reporting programs as a means 
of reassuring national and international patients, patient 
advocates, insurances and other sponsoring bodies. It 
seems reasonable to assume that if quality standards are 
assured, expertise is higher and costs are much lower, 
there might be the potential for patient attraction. Why 
should an insurances or national health systems refuse to 
cover a patient willing, for example, to go from the UK to 
Pakistan in centers that have much more experience on 
specific diseases, e.g. Thalassemia, where appropriate 
quality standards are assured, outcome reporting is 
transparent and BMT costs are much less 
BMT for thalassemia offers several advantages for startup 
centers in LMICs: a) it is the least expensive and simplest 
form of allogeneic BMT with relatively basic technology 
requirements; b) being a chronic disease there is enough 
time to adequately prepare patients in order to maximize 
initial success rates; c) high commitment and compliance 
of affected families; d) children generally enjoy high cure 
rates and excellent HRQoL; e) high cost-effectiveness; f) 
potential for leading expertise and patient attraction. 
C o n c l u s i o n  
BMT consists of a wide array of procedures which have 
very different complexities, outcomes and costs. The one 
used to cure young children with severe 
hemoglobinopathies having a compatible sibling sits on 
the simplest side of this spectrum, it's far less expensive 
than long-term supportive care and can restore a normal 
quality of life in most patients. It does not require complex 
hospital environments or undue sophisticated 
technologies. It can save the life of many children while 
being a great opportunity for health care strengthening, 
professional motivation and higher medical education. 
BMT may have positive ripple effects on institutions taking 
over the challenge as well as on screening and prevention 
programs in LMICs 
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